Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

Autor: Rieger, M. ^*, Österborg, A., Pettengell, R., White, D., Gill, D., Walewski, J., Kuhnt, E., Loeffler, M., Pfreundschuh, M., Ho, A.D.

Publikováno v: In Annals of Oncology March 2011 22(3):664-670

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Autor: Pfreundschuh M, Ho AD, Cavallin Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial Group, ZINZANI, PIER LUIGI

Publikováno v: The Lancet. Oncology. 9(5)

The definition and role of bulky disease in young patients (ie, aged 18-60 years) with good-prognosis diffuse large-B-cell lymphoma (DLBCL), who have been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-like chemother

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9707b2c1119302879cc29b133062ffae
https://pubmed.ncbi.nlm.nih.gov/18452849

[Study protocol of the VISEP study. Response of the SepNet study group]

Autor: Reinhart, K, Brunkhorst, F M, Engel, C, Bloos, F, Meier-Hellmann, A, Ragaller, M, Weiler, N, Moerer, O, Gruendling, M, Oppert, M, Grond, S, Olthoff, D, Jaschinski, U, John, S, Rossaint, R, Welte, T, Schaefer, M, Kern, P, Kuhnt, E, Kiehntopf, M, Deufel, T, Hartog, C, Gerlach, H, Stüber, F, Volk, H-D, Quintel, M, Loeffler, M

Publikováno v: Reinhart, K; Brunkhorst, F M; Engel, C; Bloos, F; Meier-Hellmann, A; Ragaller, M; Weiler, N; Moerer, O; Gruendling, M; Oppert, M; Grond, S; Olthoff, D; Jaschinski, U; John, S; Rossaint, R; Welte, T; Schaefer, M; Kern, P; Kuhnt, E; Kiehntopf, M; ... (2008). [Study protocol of the VISEP study. Response of the SepNet study group]. Anaesthesist, 57(7), pp. 723-8. Heidelberg: Springer-Medizin-Verlag 10.1007/s00101-008-1391-1

In the commentary by Zander et al. the authors appear concerned about the methods and results of our, at that time, unpublished sepsis trial evaluating hydroxyethyl starch (HES) and insulin therapy. Unfortunately, the authors' concerns are based on f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a82b9b5b3cc49947c1eaada1a4a30842
https://boris.unibe.ch/27299/1/Reinhart2008_Article_StudienprotokollDerVISEP-Studi.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.